liposomal
information and resources from the National Cancer Institute
|
|
|
|
news articles
Fighting inflammation with targeted liposomal therapy Mar 28, 2006
EurekAlert (press release), ...in the April 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), indicate the promise of targeted liposomal therapy for ...
Alnylam Announces New Collaboration and Agreements for Key ... Mar 27, 2006
PharmaLive.com (press release), ...announced the publication in Nature of the first demonstration of therapeutic gene silencing in primates with systemic RNAi using liposomal delivery technology ...
Sandia Researchers Develop a Range of Novel Platinum ... Mar 30, 2006
Newswire Today (press release), Together with their previous work, this presents a comprehensive study of the use of liposomal templating and the photocatalytic seeding strategy to produce a ...
Nanoliposome Delivers Anticancer Drug to Brain Tumors, Avoids ... Mar 25, 2006
Nanotechwire.com, ...stabilized liposome they have created and the methods they used to load approximately 10,000 molecules of the anticancer drug CPT-11 per liposomal nanoparticle ...
INEX Releases 2005 Operating Results Mar 30, 2006
CNW Telbec (Communiqués de presse), ...completed the partnering of its Targeted Chemotherapy products at which time INEX will continue development of a second generation liposomal delivery platform ...
Alnylam Pharma Signs Agreements To Have Access To Liposome ... Mar 27, 2006
Trading Markets, Alnylam said it has the option to take worldwide exclusive licenses to use Inex's liposomal technology for RNAi therapeutics directed to specific gene targets ...
Alnylam Pharmaceuticals Announces Collaboration Providing Access ... Mar 27, 2006
Trading Markets, ...also announced the publication in Nature of first demonstration of therapeutic gene silencing in primates with systemic RNAi using liposomal delivery technology ...
Alnylam Pharma Inks Two Deals Enabling Technology Access For ... Mar 27, 2006
Trading Markets, Under the agreement, Alnylam has the option to take exclusive licenses to liposomal technology developed by Inex for RNAi therapeutics targeting disease ...
RNAi Works In Monkeys Mar 27, 2006
Chemical & Engineering News Tracy S. Zimmermann and coworkers gave monkeys a single injection of a short interfering RNA (siRNA) in a liposomal formulation optimized for delivery to the ...
Liposomes With Steroid Payloads Target Arthritis Inflammation Mar 29, 2006
CNN ...corticosteroid was not used as a control in these experiments, previous work has shown dramatic differences in efficacy of nontargeted liposomal steroid over ...
Alnylam strikes deals for systemic RNAi delivery technology Mar 28, 2006
Pharmaceutical Business Review ...in the scientific journal Nature of the first demonstration of therapeutic gene silencing in primates with systemic RNAi using liposomal delivery technology. ...
RNAi works in monkeys Mar 27, 2006
Scientist, The researchers encapsulated the siRNAs in a liposomal formulation designed to target the liver, and modified their backbones to prevent siRNA degradation. ...
Hana Biosciences to License Three Targeted Cancer Drug Candidates ... Mar 17, 2006
Genetic Engineering News, Sphingosomal encapsulation is a new generation liposomal drug delivery platform, which significantly increases tumor targeting and duration of exposure for ...
Hana Biosciences to License Three Targeted Cancer Drug Candidates ... Mar 17, 2006
Finanzen.net, Sphingosomal encapsulation is a new generation liposomal drugdelivery platform, which significantly increases tumor targeting andduration of exposure for cell ...
Biomira Inc. announces year-end results Mar 9, 2006
Yahoo! News (press release) BGLP40 is a third generation vaccine program utilizing a liposomal formulation of a vaccine with human MUC1 peptide antigens, carbohydrate antigens and a ...
Body, Heal Thyself Mar 26, 2006
Chemical & Engineering News The most advanced liposomal vaccine to come out of the company's program is L-BLP25, which targets MUC1, a protein found on the surface of non-small-cell lung ...
Recent Advances in Novel Drug Delivery Systems Mar 24, 2006
AZoNano.com, ...impantable polymer systems €5.4B, transdermal €9.6B, transnasal €12.0B, pulmonary €17.0B, transmucosal €4.9B, rectal €0.9B, liposomal drug delivery ...
Research and Markets Adds Nanotechnology for Drug Discovery and ... Mar 27, 2006
GenomicsProteomics.com (press release), Nanotechnologies for biological applications already in use include liposomal drug-delivery agents, transfection agents, and magnetic resonance imaging ...
INEX and Alnylam Announce Research Collaboration for Systemic ... Mar 27, 2006
Yahoo! News (press release) Pharmaceuticals, Inc. (Nasdaq: ALNY - News) to evaluate Alnylam's RNAi therapeutics with INEX's systemic liposomal delivery technology. The ...
Bayer Makes Move To Buy Schering AG Mar 25, 2006
Medical News Today (press release), ...testing. Another promising product in this therapeutic area is a liposomal formulation of Kogenate® that is under development. ...
INEX and Alnylam Announce Research Collaboration for Systemic ... Mar 27, 2006
PharmaLive.com (press release), Alnylam Pharmaceuticals, Inc. to evaluate Alnylam's RNAi therapeutics with INEX's systemic liposomal delivery technology. The work ...
(BW) Endovasc to Attend BIO 2006 Annual International Convention Mar 22, 2006
Houston Chronicle, Endovasc's subsidiaries include: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg ...
Matrix Metalloproteinase Inhibitor Effective for Kaposi’s ... Mar 22, 2006
Cancer Consultants (press release), Patients with AIDS-related Kaposi’s sarcoma are initially treated with Doxil (liposomal doxorubicin) or combination chemotherapy with doxorubicin, bleomycin ...
Studies add new findings to vaccines delivery body of knowledge Mar 16, 2006
TMCnet Keywords: Lanark, Scotland, Vaccine Delivery, Vaccine Development, DNA Vaccine, Gene Therapy, Liposomal Delivery, Liposomes, Immunology, Immunotherapy. ...
Lorus Publishes studies on three distinct lines of research ... Mar 1, 2006
PR Newswire (press release), The study also showed that liposomal ML-220 retained anti-proliferative activity against human ovarian and breast cancer cell lines in vitro and significant in ...
Lessons From and Cautions About Noninferiority and Equivalence ... Mar 7, 2006
Journal of American Medical Association (subscription), ...was in agreement with the analysis plan for the trial, voriconazole was even statistically significantly inferior to the control drug, liposomal amphothericin B ...
IDM and Medison Pharma Sign an Exclusive Marketing Agreement for ... Mar 14, 2006
PR Newswire (press release), About Junovan(TM) Junovan(TM) is a liposomal formulation of MTP-PE (Muramyl Tripeptide Phosphatidylethanolamine) specifically designed for in vivo targeting of ...
IDM and Medison Pharma Sign an Exclusive Marketing Agreement for ... Mar 14, 2006
Yahoo! News (press release) Junovan(TM) is a liposomal formulation of MTP-PE (Muramyl Tripeptide Phosphatidylethanolamine) specifically designed for in vivo targeting of macrophages by ...
Celsion Announces 1-for-15 Reverse Stock Split; Stockholder ... Feb 27, 2006
Genetic Engineering News, We have demonstrated our ability to initiate and execute a development program for our heat activated liposomal doxorubicin drug, ThermoDox(TM), including ...
NeoPharm Announces Fiscal 2005 Financial Results Feb 28, 2006
Genetic Engineering News, Also, we continue to make progress in our liposomal technology through an ongoing dialogue with the FDA to discuss the appropriate regulatory pathway. ...
Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ... Feb 28, 2006
Cancer Consultants (press release), A US multicenter trial has reported that a regimen of Doxil (pegylated liposomal doxorubicin), vincristine and dexamethasone is associated with less toxicity ...
IDM plans to file Junovan NDA this year Feb 28, 2006
United Press International In a phase 3 study Junovan, a liposomal formulation of MTP-PE, improved disease-free survival by 25 percent and overall survival by 30 percent.
|
|
